Page 1,489«..1020..1,4881,4891,4901,491..1,5001,510..»

CSL adding scalable stem cell gene therapy tech in $91m Calimmune buy – BioPharma-Reporter.com

Posted: August 30, 2017 at 11:49 am

CSL Behring will launch itself into the stem cell gene therapy through the acquisition of Calimmune, adding a preclinical candidate and two manufacturing efficiency technologies.

CSL Behring is set to pay $91m (76m) upfront and up to $325m in milestone payments over the next eight years for Calimmune.

According to spokeswoman Natalie de Vane, the acquisition is the first step into the cell and gene therapy space for CSL with the addition of an ex vivo hematopoietic stem cell (HSC) gene therapy candidate and R&D facilities in Pasadena, California, and Sydney, Australia a natural complement to the firms protein-replacement business and its rare diseases focus.

We have been interested in the field for some time, and believe that Calimmune is an appropriate point of entry into this area for us, and a good strategic fit for our business and our longer-term strategic goals, she told Biopharma-Reporter.

Calimmunes preclinical hematopoietic stem cell (HSC) gene therapy, CAL-H, for the treatment of sickle cell disease and -thalassemia, aligns nicely with our deep expertise and leadership in haematology.

Commercial manufacturing platforms

The deal also brings CSL the Select+ and Cytegrity platform technologies which de Vane told us have broad applications in other ex vivo stem cell gene therapies.

[The platforms] have the potential to address some of the major challenges currently associated with the commercialisation of stem cell therapies, such as the ability to manufacture consistent, high-quality product, and to improve engraftment, patient to patient variability, efficacy and tolerability.

The Select+ platform, for example, looks to reduce the required intensity of the conditioning chemotherapy currently used, which could make HSC therapy an outpatient procedure, while the Cytegrity tech looks to provide a scalable manufacturing platform with high batch-to-batch consistency.

[This] would be a tremendous advantage as today lentiviral vectors are generally manufactured in small batches through a convoluted process, she said.

The deal is expected to close in the next two weeks at which point CSL will hope to integrate the business with minimal disruption.

Immediately after close, Louis Breton, Calimmunes CEO, will report directly to our Chief Scientific Officer and R&D Director, Andrew Cuthbertson. Additionally, we will form a joint integration team focused on growing and building the Calimmune assets and technologies.

Excerpt from:
CSL adding scalable stem cell gene therapy tech in $91m Calimmune buy - BioPharma-Reporter.com

Posted in Gene therapy | Comments Off on CSL adding scalable stem cell gene therapy tech in $91m Calimmune buy – BioPharma-Reporter.com

Regenxbio to buy battered Dimension for gene therapies – FierceBiotech

Posted: August 30, 2017 at 11:49 am

Regenxbio has penned a deal to acquire Dimension Therapeutics. The takeover will see Regenxbio pay about $86 million to add two of early-stage gene therapies to its pipeline.

Rockville, Maryland-based Regenxbio swooped on Dimension to gain the rights to DTX301 and DTX401. DTX301 is the more advanced of the candidates, having already moved into a phase 1/2 trial in patients with late-onset ornithine transcarbamylase deficiency.

Regenxbio expects glycogen storage disease type Ia candidate DTX401 to reach the IND stage early next year, boosting the depth of its pipeline.

We believe that DTX301 and DTX401 are product candidates that address diseases with high unmet need and will become an important part of a strong internal pipeline at Regenxbio that has the potential to achieve multiple milestones through the end of 2018, Regenxbio CEO Kenneth Mills said in a statement. The deal also gives Regenxbio a stake in Bayer-partnered hemophilia A gene therapy DTX201.

The notable absence from the list of programs Regenxbio is excited aboutand the reason it is set to buy Dimension for a knockdown priceis DTX101. That was once Dimensions top prospect. But the release of data from a phase 1/2 trial of the hemophilia B candidate over the first half of the year marked it out as unlikely to succeed, particularly in light of clinical data generated by Spark Therapeutics rival gene therapy.

That setback means the takeout by Regenxbio is a small, low-key exit for the once hard-charging biotech.

Dimension grew out of Fidelity Biosciences belief gene therapy was ready for the big time. And, having been spawned through an alliance with ReGenX, Dimension quickly pulled in $30 million from Fidelity and OrbiMed, was heralded as having the best AAV technology in the industry, landed a $250 million deal with Bayer, signed up Merck KGaA chief Annalisa Jenkins as CEO and capped off a busy first year with a Fierce 15 award. An IPO followed late in 2015.

That was about as good as it got for Dimension.

This year, the biotechs A-list credentials butted up against negative data. The negative data won. Dimensions market cap went on to slip to $30 million, attracting the interest of Regenxbio. A bid worth about three times Dimensions pre-news market cap proved enough to get the fallen gene therapy star to sign on the dotted line.

Shares in Dimension rose about 160% in premarket trading.

See the article here:
Regenxbio to buy battered Dimension for gene therapies - FierceBiotech

Posted in Gene therapy | Comments Off on Regenxbio to buy battered Dimension for gene therapies – FierceBiotech

Abeona Gene Therapy for Epidermolysis Bullosa Continues to Impress the FDA – Rare Disease Report

Posted: August 30, 2017 at 11:49 am

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy to Abeona Therapeutics EB-101 gene therapy for epidermolysis bullosa (EB).EB patients have extremely delicate skin, often referred to as butterfly skin, because it becomes fragile like the wings of a butterfly and can fall apart at the touch.The disorder makes patients susceptible to blisters and poor healing of wounds. Recessive dystrophic epidermolysis bullosais the most severe form of the condition, and is the result of a mutation in COL7A1 gene, which encodes for collagen VII. Abeonas EB-101 is a skin graft that includes a healthy COL7A1 gene.

Breakthrough Therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions and it was granted based on data from the Phase 1/2 clinical trial showing significant wound healing (greater than 50% healed) over a 2-year period.

The EB-101 program has already been granted Orphan Drug and Rare Pediatric Disease Designations from the FDA and Orphan Drug Designation from theEuropean Medicines Agency(EMA).

EB-101 is an autologous gene-corrected cell therapeutic approach that utilizes a patients own cells and genetically engineering them to produce the correct version of collagen, which helps hold skin on to the body, thereby reducing the number of painful blisters caused by injury and improving wound healing, stated Timothy J. Miller, Ph.D., Abeonas President and CEO. We are grateful that the FDA has recognized the promising clinical data from the EB-101 program with Breakthrough Therapy designation and look forward to initiating our pivotal Phase 3 trial as we advance EB-101 for patients with this debilitating disease.

In May of this year, data from the Phase 1/2 trial were presented at the Society of Investigative Dermatology (SID) conference by Stanford collaborators, and demonstrated that EB-101 treated wounds were significantly healed >50% for more than two years post-administration. The data included:

An example of wound healing that occurred using the gene therapy is shown below.

Look for out exclusive interview with Dr. Miller later this week when we talk to him about EB-101 and the companys other gene therapies.

For more information on FDA applications, designations and approvals, followRare Disease ReportonFacebookandTwitter. For up-to-the-minute breaking news, sign up for theRDRe-newsletter..

See original here:
Abeona Gene Therapy for Epidermolysis Bullosa Continues to Impress the FDA - Rare Disease Report

Posted in Gene therapy | Comments Off on Abeona Gene Therapy for Epidermolysis Bullosa Continues to Impress the FDA – Rare Disease Report

FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments – KNAU Arizona Public Radio

Posted: August 30, 2017 at 11:49 am

The Food and Drug Administration is cracking down on "unscrupulous" clinics selling unproven and potentially dangerous treatments involving stem cells.

Hundreds of clinics around the country have started selling stem cell therapies that supposedly use stem cells but have not been approved as safe and effective by the FDA, according to the agency.

"There are a small number of unscrupulous actors who have seized on the clinical promise of regenerative medicine, while exploiting the uncertainty, in order to make deceptive, and sometimes corrupt assurances to patients based on unproven and, in some cases, dangerously dubious products," FDA Commissioner Scott Gottlieb said in a statement Monday.

The FDA has taken action against clinics in California and Florida.

The agency sent a warning letter to the US Stem Cell Clinic of Sunrise, Fla., and its chief scientific officer, Kristin Comella, for "marketing stem cell products without FDA approval and significant deviations from current good manufacturing practice requirements."

The clinic is one of many around the country that claim to use stem cells derived from a person's own fat to treat a variety of conditions, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and lung and heart diseases, the FDA says.

The Florida clinic had been previously linked to several cases of blindness caused by attempts to use fat stem cells to treat macular degeneration.

The FDA also said it has taken "decisive action" to "prevent the use of a potentially dangerous and unproven treatment" offered by StemImmune Inc. of San Diego, Calif., and administered to patients at California Stem Cell Treatment Centers in Rancho Mirage and Beverly Hills, Calif.

As part of that action, the U.S. Marshals Service seized five vials of live vaccinia virus vaccine that is supposed to be reserved for people at high risk for smallpox but was being used as part of a stem-cell treatment for cancer, according to the FDA. "The unproven and potentially dangerous treatment was being injected intravenously and directly into patients' tumors," according to an FDA statement.

Smallpox essentially has been eradicated from the planet, but samples are kept in reserve in the U.S. and Russia, and vaccines are kept on hand as a result.

But Elliot Lander, medical director of the California Stem Cell Treatment Centers, denounced the FDA's actions in an interview with Shots.

"I think it's egregious," Lander says. "I think they made a mistake. I'm really baffled by this."

While his clinics do charge some patients for treatments that use stem cells derived from fat, Lander says, none of the cancer patients were charged and the treatments were administered as part of a carefully designed research study.

"Nobody was charged a single penny," Lander says. "We're just trying to move the field forward."

In a written statement, U.S. Stem Cell also defended its activities.

"The safety and health of our patients are our number one priority and the strict standards that we have in place follow the laws of the Food and Drug Administration," according to the statement.

"We have helped thousands of patients harness their own healing potential," the statement says. "It would be a mistake to limit these therapies from patients who need them when we are adhering to top industry standards."

But stem-cell researchers praised the FDA's actions.

"This is spectacular," says George Daley, dean of the Harvard Medical School and a leading stem-cell researcher. "This is the right thing to do."

Daley praised the FDA's promise to provide clear guidance soon for vetting legitimate stem-cell therapies while cracking down on "snake-oil salesmen" marketing unproven treatments.

Stem-cell research is "a major revolution in medicine. It's bound to ultimately deliver cures," Daley says. "But it's so early in the field," he adds. "Unfortunately, there are unscrupulous practitioners and clinics that are marketing therapies to patients, often at great expense, that haven't been proven to work and may be unsafe."

Others agreed.

"I see this is a major, positive step by the FDA," says Paul Knoepfler, a professor of cell biology at the University of of California, Davis, who has documented the proliferation of stem-cell clinics.

"I'm hoping that this signals a historic shift by the FDA to tackle the big problem of stem-cell clinics selling unapproved and sometimes dangerous stem cell "treatments" that may not be real treatments," Knoepfler says.

Read more here:
FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - KNAU Arizona Public Radio

Posted in Arizona Stem Cells | Comments Off on FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments – KNAU Arizona Public Radio

Around the world – Bend Bulletin

Posted: August 30, 2017 at 11:49 am

A-A+

Travel ban in the courts In the latest arguments over President Donald Trumps travel ban, a three-judge panel of a federal appeals court in Seattle indicated Monday it would continue allowing grandparents and other relatives of U.S. residents to travel to the U.S. from six predominantly Muslim countries. But the judges were less forthcoming about their views on exceptions to a second part of the ban, suspending the nations refugee program. In July in a provisional ruling, the Supreme Court allowed exceptions to the ban for many relatives but not for most refugees. The Supreme Court will hear arguments in the case in October.

Stem cell clinic crackdown The Food and Drug Administration announced a crackdown on dangerous stem cell clinics Monday, while pledging to ease the path to approval for companies and doctors with legitimate treatments in the field. The agency reported actions against two large stem cell clinics and a biotech company, saying it was critical to shut down unscrupulous actors in regenerative medicine, which includes stem cell and gene therapies and immunotherapies. Stem cells can develop into many different types of cells, and are thought to have the potential to repair or replace damaged tissue. But the FDA has approved only a few stem-cell products.

Trump timed Arpaio pardon for storm ratings President Donald Trump offered a fiery defense Monday of his decision to pardon former Arizona Sheriff Joe Arpaio as Hurricane Harvey made landfall in Texas last week and claimed he timed it to attract maximum attention as television viewers were glued to storm coverage. Trump also suggested the Justice Department had political motives during the Obama administration for charging the former sheriff in a case concerning his illegal profiling of Hispanics. Actually, in the middle of a hurricane, even though it was a Friday evening, I assumed the ratings would be far higher than they were normally, Trump said.

European migrant influx Measures intended to stop migrants from trying to cross the Mediterranean were at the center of discussions in Paris among four European leaders who met with the leaders of three African countries Monday. The meeting, billed as a minisummit, brought together the leaders of France, Germany, Italy and Spain as well as Chad and Niger and one of Libyas leaders. Chad and Niger are transit countries for people fleeing war or poverty, while Libya is a departure point for crossing the Mediterranean and a center for traffickers who promise to get people to Europe.

Kenyas strict plastic bag ban Kenya will now punish with up to four years in jail anyone making, selling or importing plastic bags, putting in place one of the worlds toughest bans on the ubiquitous item that is blamed for clogging oceans and killing marine life. The rule, announced in March and put into effect Monday, also means garbage bags will be taken off supermarket shelves and visitors entering Kenya will be required to leave duty-free shopping bags at the airport. Kenya joins more than 40 other countries including China, the Netherlands and France that have introduced taxes on bags or limited their use.

German nurse suspect in 86 deaths A German nurse serving a life sentence for murdering two of his patients is believed to have killed at least 86 people entrusted to his care, officials said Monday, in what they described as an imagination-defying series of crimes. The nurse, identified as Niels Hoegel, was sentenced to life in February 2015, after a court found him guilty of administering overdoses of heart medication to some patients in an intensive care ward where he worked from 1999 to 2001. He was convicted of two counts of murder, two counts of attempted murder and causing bodily harm to patients and is serving his sentence. During his trial, the former nurse confessed to intentionally inducing cardiac crises in 90 of his patients, 30 of whom he said had died. That prompted officials to launch an investigation into the deaths of some 130 of Hoegels former patients. The results were presented Monday in Oldenburg. Authorities are waiting for the results of 41 toxicology reports, the results of which could drive the number of confirmed deaths even higher

Indian guru rape sentencing An Indian court sentenced a well-known guru to at least 10 years in prison for rape Monday, three days after followers angered by his conviction engaged in violent protests. Gurmeet Ram Rahim Singh was found guilty Friday of having raped two women more than a decade ago. Thousands of Singhs followers had gathered in the state where the verdict was announced. They responded by smashing cars, setting fire to buildings and attacking police officers, and the violence later spread to other cities in northern India. At least 38 people were killed, and more than 250 were injured.

Border dispute in Asia India and China agreed Monday to back away from their confrontation over a tiny slice of territory high in the Himalayas, easing tensions between the worlds two most populous countries. Both sides agreed to give some ground in order to end the standoff. In a short statement, the Indian government said it had reached an understanding with Beijing. China seemed willing to compromise but still claims the territory.

18069661

See the rest here:
Around the world - Bend Bulletin

Posted in Arizona Stem Cells | Comments Off on Around the world – Bend Bulletin

FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments – Utah Public Radio

Posted: August 30, 2017 at 11:48 am

The Food and Drug Administration is cracking down on "unscrupulous" clinics selling unproven and potentially dangerous treatments involving stem cells.

Hundreds of clinics around the country have started selling stem cell therapies that supposedly use stem cells but have not been approved as safe and effective by the FDA, according to the agency.

"There are a small number of unscrupulous actors who have seized on the clinical promise of regenerative medicine, while exploiting the uncertainty, in order to make deceptive, and sometimes corrupt assurances to patients based on unproven and, in some cases, dangerously dubious products," FDA Commissioner Scott Gottlieb said in a statement Monday.

The FDA has taken action against clinics in California and Florida.

The agency sent a warning letter to the US Stem Cell Clinic of Sunrise, Fla., and its chief scientific officer, Kristin Comella, for "marketing stem cell products without FDA approval and significant deviations from current good manufacturing practice requirements."

The clinic is one of many around the country that claim to use stem cells derived from a person's own fat to treat a variety of conditions, including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and lung and heart diseases, the FDA says.

The Florida clinic had been previously linked to several cases of blindness caused by attempts to use fat stem cells to treat macular degeneration.

The FDA also said it has taken "decisive action" to "prevent the use of a potentially dangerous and unproven treatment" offered by StemImmune Inc. of San Diego, Calif., and administered to patients at California Stem Cell Treatment Centers in Rancho Mirage and Beverly Hills, Calif.

As part of that action, the U.S. Marshals Service seized five vials of live vaccinia virus vaccine that is supposed to be reserved for people at high risk for smallpox but was being used as part of a stem-cell treatment for cancer, according to the FDA. "The unproven and potentially dangerous treatment was being injected intravenously and directly into patients' tumors," according to an FDA statement.

Smallpox essentially has been eradicated from the planet, but samples are kept in reserve in the U.S. and Russia, and vaccines are kept on hand as a result.

But Elliot Lander, medical director of the California Stem Cell Treatment Centers, denounced the FDA's actions in an interview with Shots.

"I think it's egregious," Lander says. "I think they made a mistake. I'm really baffled by this."

While his clinics do charge some patients for treatments that use stem cells derived from fat, Lander says, none of the cancer patients were charged and the treatments were administered as part of a carefully designed research study.

"Nobody was charged a single penny," Lander says. "We're just trying to move the field forward."

In a written statement, U.S. Stem Cell also defended its activities.

"The safety and health of our patients are our number one priority and the strict standards that we have in place follow the laws of the Food and Drug Administration," according to the statement.

"We have helped thousands of patients harness their own healing potential," the statement says. "It would be a mistake to limit these therapies from patients who need them when we are adhering to top industry standards."

But stem-cell researchers praised the FDA's actions.

"This is spectacular," says George Daley, dean of the Harvard Medical School and a leading stem-cell researcher. "This is the right thing to do."

Daley praised the FDA's promise to provide clear guidance soon for vetting legitimate stem-cell therapies while cracking down on "snake-oil salesmen" marketing unproven treatments.

Stem-cell research is "a major revolution in medicine. It's bound to ultimately deliver cures," Daley says. "But it's so early in the field," he adds. "Unfortunately, there are unscrupulous practitioners and clinics that are marketing therapies to patients, often at great expense, that haven't been proven to work and may be unsafe."

Others agreed.

"I see this is a major, positive step by the FDA," says Paul Knoepfler, a professor of cell biology at the University of of California, Davis, who has documented the proliferation of stem-cell clinics.

"I'm hoping that this signals a historic shift by the FDA to tackle the big problem of stem-cell clinics selling unapproved and sometimes dangerous stem cell "treatments" that may not be real treatments," Knoepfler says.

Read more here:
FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - Utah Public Radio

Posted in Utah Stem Cells | Comments Off on FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments – Utah Public Radio

About Us, Midwest Stem Cell Therapy Center – KUMC

Posted: August 30, 2017 at 11:48 am

In July 2013, the Midwest Stem Cell Therapy Center (MSCTC) was created by Kansas Legislature with the mission to facilitate existing research and therapy on a global level, as well as to establish a frontier for other research and therapies for patients suffering from diseases.

Funded initially through State appropriation, the Center also operates off the generosity of donors through the University of Kansas Endowment Association. The 15-member advisory board is composed of members appointed by the governer, the House, Senate, Board of Regents and several other stakeholder entities.

The law creating the center took effect on July 1, 2013. KU Medical Center Executive Vice Chancellor Douglas Girod, M.D. appointed Buddhadeb Dawn, M.D., to serve as the center's executive director. A 15-member advisory has been assembled, with members appointed by the governor, the House, the Senate, the Board of Regents and several other stakeholder entities throughout the state.

Adult stem cell treatments have been used clinically to successfully treat leukemia and related bone/blood cancers using bone marrow transplantation. KU Medical Center has been involved in research using the solid part of the umbilical cord (Wharton's jelly).

Besides KU Medical Center, other institutions around the state have also initiated adult stem cell research projects. However, before the MSCTC, there was no systematic mechanism for Kansans to receive adult stem cell therapy (other than bone marrow transplants for a few conditions) in the state or in the region, nor was there a coordinated center to translate basic stem cell research findings into clinical applications. The MSCTC is also working to educate the public, as well as medical professionals about adult stem cell therapeutic options, currently available or in development, that could benefit patients in need.

In addition to bone marrow transplantation, additional therapies with adult stem cells - including organ repair - have been the focus of intense attention in the scientific community in recent years.

As adult stem cell therapy is becoming more effective, many patientswill benefit. Kansas is well-positioned tocontribute to this burgeoning new field of medicine. Kansas has the opportunity to focus on development of specific areas of adult stem cell research and patient treatment, with the potential to become a world leader in patient therapies for specific diseases or conditions.

Last modified: Aug 01, 2016

Link:
About Us, Midwest Stem Cell Therapy Center - KUMC

Posted in Kansas Stem Cells | Comments Off on About Us, Midwest Stem Cell Therapy Center – KUMC

Paralyzed after pool accident, student heads back to college – Kansas City Star

Posted: August 30, 2017 at 11:48 am

Jack Massey is ready to go back to school.

Only this time, the University of Florida senior will head back to campus with his mom and a new outlook on life.

Massey suffered a spinal cord injury in a pool accident in March and is paralyzed from the chest down. After months of rehab, he's eager to get back into a familiar routine.

"It's definitely boring," the 21-year-old said at his parents' home in Niceville. "There's not a lot to do. I want to go back to school. I still have my brain. I still have everything I need to be successful."

After the accident March 17, Massey was treated at the University of Florida Shands Hospital and then was transferred to Shepherd Center, a spinal cord and brain injury rehab center in Atlanta. At Shepherd Center he met with a peer mentor, counselors and physical therapists to help him find a new normal.

Jack has remained positive throughout the past six months.

"Jack has been a fighter through all of this," said his mother, Julie. "I think he's done well. I only saw him break down once."

Before the accident, Jack was a well-rounded athlete who playing baseball and basketball and ran. He was a star on the track and field team at Niceville High School, with his 4 X 800 relay winning state his senior year.

He says the biggest challenge now is not being able to do the same things he could before.

"I can't get up and go," he said. "It didn't really start to set in until after I got out of rehab."

Jack has had to find enjoyment in other things, like reading or playing with the dogs. His friends have learned to transfer him from his wheelchair to a car so they can take him to the movies or out to eat. When they recently took a trip to the beach, Julie said five of Jack's friends carried him out to the sand a lesson on how hard it is to navigate the world in a wheelchair.

Jack said he believes technology one day will advance enough that he won't be paralyzed forever. He also volunteered to do stem cell surgery to allow doctors to study the effects of stem cells on his spine for the next 15 years. Instead of wallowing in self-pity, he's moving forward. But he'll need help.

"I'm appreciating everything in the now," he said.

Doctors have said Jack has adapted faster than expected, but there are still some everyday essential tasks that are out of his reach. He cannot write or cook. He can shower himself but can't dry himself or transfer himself in and out of his wheelchair. The Massey family hopes to secure a personal care attendant for Jack at school, but until then Julie will be in Gainesville to help him transition. An occupational therapy student from the university will also help Jack on a temporary basis.

Finding proper care for her son has proven to be a learning experience for Julie and her husband, Lance.

"I don't know how people do it," she said. "We have good health care, but then there's hidden costs. There's travel expenses. ... It's kind of humbling. Nobody should have to go to GoFundMe for medical help."

Jack wants to spend his final year as an undergrad as independent as possible. After months of helping him recover, Julie said it will be hard to let her son go. Jack is the oldest of three; his brother Lance is 19 and a student at UF and his sister Alina is 14 and attends Ruckel Middle School.

"It's like letting him go off to kindergarten again," she said.

As for life after college, Jack said he doesn't feel limited in career choices. One of his professors in the geology department encouraged him by saying that there were plenty of opportunities he could pursue in that field. Jack said he may also consider law school. One thing he's learned through this life-altering experience is that there are no limits to what he can achieve.

"I haven't done that much deep thinking. I just go with the flow," he said. "But I learned I have more perseverance. I'm more mentally tough than I thought I was. I'm appreciative for life in general. That's one of the big things."

Read more:
Paralyzed after pool accident, student heads back to college - Kansas City Star

Posted in Kansas Stem Cells | Comments Off on Paralyzed after pool accident, student heads back to college – Kansas City Star

Molecular Medicine | University of Maryland School of Medicine

Posted: August 30, 2017 at 11:47 am

The Graduate Program in Molecular Medicine at the University of Maryland Baltimore offers research and training opportunities with internationally-renowned scientists. Our Molecular Medicine Program is an interdisciplinary program of study leading to a Ph.D. degree. There are four different research tracks: Cancer Biology, Genome Biology, Molecular and Cell Physiology, and Toxicology and Pharmacology. Each provides for a unique interdisciplinary research and graduate training experience that is ideally suited for developing scientists of the post-genomic era.

Faculty mentors in this graduate program are leaders in their respective research areas and reside in various departments and Organized Research Centers in the School of Medicine and Dental School, the Institute for Genomic Sciences (IGS), the Institute of Human Virology (IHV), the Marlene and Stewart Greenebaum Cancer Center, and the Center for Vascular and Inflammatory Diseases (CVID). The over 150 faculty in the Graduate Program in Molecular Medicine are internationally recognized for their research in biotechnology, cancer, cardiovascular and renal biology, functional genomics and genetics, membrane biology, muscle biology, neuroscience and neurotoxicology, reproduction and vascular biology.

Read more here:
Molecular Medicine | University of Maryland School of Medicine

Posted in Molecular Medicine | Comments Off on Molecular Medicine | University of Maryland School of Medicine

TCI woman fell 31 floors, due to work in molecular medicine in Malaysia – Magnetic Media (press release)

Posted: August 30, 2017 at 11:47 am

Share

Share

Share

Email

Thailand, August 28, 2017 An investigation is launched in Thailand after a woman fell from the 31stfloor of a hotel to her death, that woman is a Turks and Caicos Islander identified as #MaxineVerniceMissick. Missick was a medical student studying at Keele University in the UK but was on a trip to Thailand when she somehow plunged to her death and was found in an alley between two hotels with a broken neck and other broken bones around 5am Friday.

The 23 year old is a graduate of Clement Howell High, and had reportedly been accepted recently to work at the Institute for Molecular Medicine Research in Penang, Malaysia. Police explained that her room was not ransacked, that her hotel room door was locked and that Missick checked in, alone and arrived in the country on August 18. Her hotel check out date was August 31.

Friends of Maxine, who was described as a British citizen in news reports out of Thailand is also Haitian and was called a woman who loved the Lord, loved African culture, always had a smile on her face and loved meeting people.

Police in Thailand have not ruled out suicide, promise a thorough investigation and say an autopsy will be performed to determine exact cause of death. Condolences to Maxines friends and family.

#MagneticMediaNews

More here:
TCI woman fell 31 floors, due to work in molecular medicine in Malaysia - Magnetic Media (press release)

Posted in Molecular Medicine | Comments Off on TCI woman fell 31 floors, due to work in molecular medicine in Malaysia – Magnetic Media (press release)

Page 1,489«..1020..1,4881,4891,4901,491..1,5001,510..»